2m 2m 2m 2m 2m 2m 2m
VOR BIOPHARMA (VOR)
NASDAQ
$13.43-$0.01 (-0.11%)
Price as of Jun 03, 2026 6:46 PM EDT- $811.2MMarket Cap
- 193.83%1-Year Change
- BiotechnologyIndustry
VOR BIOPHARMA (VOR)
$13.43-$0.01 (-0.11%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cost of Revenue | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Gross Profit | 0 N/A | 0 N/A | 0 N/A | 0 N/A | |
Sales and Marketing Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Research and Development Expense | -321.5M +244.58% | -93.3M -1.07% | -94.3M +46.11% | -64.5M +35.81% | |
Depreciation and Amortization Expense | 2.9M -18.17% | 3.5M +1.03% | 3.5M +38.30% | 2.5M +76.08% | |
Total Operating Expenses | 371.6M +206.67% | 121.2M -3.85% | 126.0M +34.92% | 93.4M +35.35% | |
Operating Profit | -371.6M +206.67% | -121.2M -3.85% | -126.0M +34.92% | -93.4M +35.35% | |
Interest Income | 5.9M +37.39% | 4.3M -47.74% | 8.2M +517.30% | 1.3M +1,012.61% | |
Interest Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Income and Expense and Net | 5.9M +37.39% | 4.3M -47.74% | 8.2M +517.30% | 1.3M +1,012.61% | |
Total Nonoperating Income and Expense | -324.3M -7,693.98% | 4.3M -47.74% | 8.2M +517.30% | 1.3M +1,012.61% | |
Income before Taxes | -371.6M +206.67% | -121.2M -3.85% | -126.0M +36.86% | -92.1M +31.32% | |
Income Taxes | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -696.0M +495.29% | -116.9M -0.81% | -117.9M +27.98% | -92.1M +33.67% | |
Net Income from Continuing Operations Applicable to Common | -696.0M +495.29% | -116.9M -0.81% | -117.9M +27.98% | -92.1M +31.32% | |
Basic EPS and Net Income | -70.50 +4,047.06% | -1.70 -2.86% | -1.75 -24.89% | -2.33 +10.95% | |
Diluted EPS and Net Income | -70.50 +4,047.06% | -1.70 -2.86% | -1.75 -24.89% | -2.33 +10.95% | |
Basic Weighted Average Shares | 9.9M -85.63% | 68.7M +2.25% | 67.2M +69.89% | 39.6M +18.30% | |
Diluted Weighted Average Shares | 9.9M -85.63% | 68.7M +2.25% | 67.2M +69.89% | 39.6M +18.30% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 396.5M +383.82% | 81.9M +161.32% | 31.4M -45.66% | 57.7M -51.83% | |
Short-Term Investments | 58.7M +488.57% | 10.0M -90.57% | 105.8M -38.67% | 172.5M +96.81% | |
Cash and Cash Equivalents and Short-Term Investments | 455.2M +395.19% | 91.9M -32.99% | 137.2M -40.42% | 230.2M +10.98% | |
Total Current Assets | 458.1M +374.69% | 96.5M -31.46% | 140.8M -40.58% | 236.9M +10.52% | |
Accumulated Depreciation | 25,000 -99.78% | 11.2M +38.60% | 8.1M +75.51% | 4.6M +121.21% | |
Property and Plant and Equipment and Net | 533,000 -91.90% | 6.6M -34.52% | 10.1M -20.45% | 12.6M +84.36% | |
Total Long-Term Assets | 2.4M +0.04% | 2.4M -50.48% | 4.8M +64.51% | 2.9M -10.14% | |
Total Assets | 464.1M +224.81% | 142.9M -27.88% | 198.1M -33.82% | 299.4M +23.40% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Current Liabilities | 25.2M +35.24% | 18.6M +19.52% | 15.6M +18.70% | 13.1M +29.21% | |
Total Long-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Long-Term Liabilities | 603.3M +2,084.56% | 27.6M -13.24% | 31.8M -10.69% | 35.6M +120.35% | |
Total Liabilities | 628.4M +1,259.46% | 46.2M -2.48% | 47.4M -2.78% | 48.8M +85.21% | |
Retained Earnings | -1.2B +152.30% | -457.0M +34.38% | -340.1M +53.04% | -222.2M +70.77% | |
Total Stockholders Equity | -164.3M -269.98% | 96.7M -35.87% | 150.7M -39.86% | 250.6M +15.88% | |
Total Shares Outstanding | 38.7M -68.97% | 124.8M +83.79% | 67.9M +2.87% | 66.0M +77.53% | |
Cash Flow | |||||
Cash from Operating Activities | -142.7M +43.20% | -99.7M -0.63% | -100.3M +17.79% | -85.1M +23.14% | |
Capital Expenditures | 941,000 +310.92% | 229,000 -78.58% | 1.1M -87.37% | 8.5M +117.31% | |
Cash from Investing Activities | -48.8M -150.39% | 96.9M +36.40% | 71.0M +175.47% | -94.1M +2.66% | |
Dividends Paid | 0 N/A | 0 N/A | 0 N/A | 0 N/A | |
Cash from Financing Activities | 503.8M +843.60% | 53.4M +1,717.29% | 2.9M -97.49% | 117.1M -49.71% | |
Financials Ratio | |||||
Gross Margin | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Operating Margin | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Return on Assets | -229.31% +234.43% | -68.57% +44.71% | -47.38% +39.42% | -33.99% N/A | |
Return on Equity | 2,057.65% +2,276.98% | -94.52% +60.92% | -58.74% +48.88% | -39.45% N/A | |
Revenue Growth | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Current Ratio | 18.20 +250.99% | 5.19 -42.65% | 9.04 -49.94% | 18.06 N/A | |
Cash Ratio | 15.75 +257.75% | 4.40 +118.63% | 2.01 -54.22% | 4.40 N/A | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow